Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)

X. Papanikolaou; A. Rosenthal; M. Dhodapkar; J. Epstein; R. Khan; F. van Rhee; Y. Jethava; S. Waheed; M. Zangari; A. Hoering; J. Crowley; D. Alapat; F. Davies; G. Morgan; B. Barlogie

doi:10.1038/BCJ.2016.19

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)

X. Papanikolaou, A. Rosenthal, M. Dhodapkar, J. Epstein, R. Khan, F. van Rhee, Y. Jethava, S. Waheed, M. Zangari, A. Hoering, J. Crowley, D. Alapat, F. Davies, G. Morgan, B. Barlogie

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English
Article number	e410
Journal	Blood Cancer Journal
Volume	6
Issue number	3
DOIs	https://doi.org/10.1038/BCJ.2016.19
State	Published - 2016
Externally published	Yes

Access to Document

10.1038/BCJ.2016.19

Cite this

Papanikolaou, X., Rosenthal, A., Dhodapkar, M., Epstein, J., Khan, R., van Rhee, F., Jethava, Y., Waheed, S., Zangari, M., Hoering, A., Crowley, J., Alapat, D., Davies, F., Morgan, G., & Barlogie, B. (2016). Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120). Blood Cancer Journal, 6(3), Article e410. https://doi.org/10.1038/BCJ.2016.19

@article{47bd6e5c6f2f47b3a8a998db8c49fd4e,

title = "Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)",

author = "X. Papanikolaou and A. Rosenthal and M. Dhodapkar and J. Epstein and R. Khan and \{van Rhee\}, F. and Y. Jethava and S. Waheed and M. Zangari and A. Hoering and J. Crowley and D. Alapat and F. Davies and G. Morgan and B. Barlogie",

note = "Funding Information: BB received research funding from Celgene Corp. and Millennium Pharmaceuticals, Inc. and is a consultant for Celgene Corp., Millennium Pharmaceuticals, Inc., Onyx Funding Information: We thank the patients and staff of the Myeloma Institute for Research and Therapy. This work was supported in part by PO1 CA 55819 from the National Cancer Institute, and in part by the following PHS/DHHS grant numbers awarded by the National Cancer Institute, National Clinical Trials Network (NCTN): CA180888, CA180819 and CA180826.",

year = "2016",

doi = "10.1038/BCJ.2016.19",

language = "English",

volume = "6",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "3",

}

Papanikolaou, X, Rosenthal, A, Dhodapkar, M, Epstein, J, Khan, R, van Rhee, F, Jethava, Y, Waheed, S, Zangari, M, Hoering, A, Crowley, J, Alapat, D, Davies, F, Morgan, G & Barlogie, B 2016, 'Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)', Blood Cancer Journal, vol. 6, no. 3, e410. https://doi.org/10.1038/BCJ.2016.19

TY - JOUR

T1 - Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)

AU - Papanikolaou, X.

AU - Rosenthal, A.

AU - Dhodapkar, M.

AU - Epstein, J.

AU - Khan, R.

AU - van Rhee, F.

AU - Jethava, Y.

AU - Waheed, S.

AU - Zangari, M.

AU - Hoering, A.

AU - Crowley, J.

AU - Alapat, D.

AU - Davies, F.

AU - Morgan, G.

AU - Barlogie, B.

N1 - Funding Information: BB received research funding from Celgene Corp. and Millennium Pharmaceuticals, Inc. and is a consultant for Celgene Corp., Millennium Pharmaceuticals, Inc., Onyx Funding Information: We thank the patients and staff of the Myeloma Institute for Research and Therapy. This work was supported in part by PO1 CA 55819 from the National Cancer Institute, and in part by the following PHS/DHHS grant numbers awarded by the National Cancer Institute, National Clinical Trials Network (NCTN): CA180888, CA180819 and CA180826.

PY - 2016

Y1 - 2016

UR - https://www.scopus.com/pages/publications/85015648607

U2 - 10.1038/BCJ.2016.19

DO - 10.1038/BCJ.2016.19

M3 - Letter

C2 - 27015287

AN - SCOPUS:85015648607

SN - 2044-5385

VL - 6

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 3

M1 - e410

ER -